Welcome to Cardiology Today – Recorded November 18, 2025. This episode summarizes 5 key cardiology studies on topics like type two diabetes and semaglutide. Key takeaway: Semaglutide Improves Peripheral Artery Disease. Article Links: Article 1: Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial. (Journal of the American College of Cardiology) Article 2: Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. (Journal of the American College of Cardiology) Article 3: Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials. (Journal of the American College of Cardiology) Article 4: Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical Trials. (Journal of the American College of Cardiology) Article 5: Adult Heart Transplant Survival in the United States: Regional and Racial Disparities From 2002 to 2022. (Transplantation) Full episode page: https://podcast.explainheart.com/podcast/semaglutide-improves-peripheral-artery-disease-11-18-25/ Featured Articles Article 1: Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial. Journal: Journal of the American College of Cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40892617 Summary: The STRIDE trial established that semaglutide 1.0 mg improved functional outcomes and health-related quality of life in patients with early symptomatic peripheral artery disease and type two diabetes. Sex-based differences are recognized in the epidemiology, clinical presentation, and outcomes of peripheral artery disease. This study explored how these existing sex differences might influence the effectiveness of semaglutide treatment in this patient population. Understanding these differential responses provides key clinical insights for optimizing individualized treatment strategies. Article 2: Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. Journal: Journal of the American College of Cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40892613 Summary: N-terminal pro-B-type natriuretic peptide is a key biomarker in heart failure guidelines for risk stratification and trial eligibility. Standard threshold levels for these natriuretic peptides typically do not incorporate measures of adiposity, such as body mass index. This gap in risk assessment highlights a significant clinical challenge in patients with heart failure with mildly reduced or preserved ejection fraction. Understanding the interplay between natriuretic peptide levels, body mass index, and clinical outcomes is crucial for more precise patient management. Article 3: Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials. Journal: Journal of the American College of Cardiology PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40892605 Summary: Obesity is a core pathophysiologic contributor to cardiovascular, kidney, and metabolic conditions. The association between various adiposity-related anthropometric measures and cardiovascular outcomes in this patient population remains an area requiring rigorous investigation. This pooled analysis of three global trials specifically investigated how different anthropometrics relate to cardiovascular outcomes and the efficacy of finerenone treatment. This research provides crucial information for understanding patient-specific responses to therapy in cardiovascular-kidney-metabolic disease. Article 4: Adiposity-Related Anthropometrics and Clinical Outcome